PeptideStack
5.2kquestions
20kanswers
220users

Does dimerisation dominate for a GLP-1 receptor agonist held at 37 °C?

Asked 15 Jun 2025Modified 10 months agoViewed 30k times
32

What I am working with: dimerisation · a GLP-1 receptor agonist · 37 °C.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

What is the causal chain, and where does it stop being established?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

646 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
shareeditfollowflag
ZA
askedzeynep_arslan20k2815 Jun 2025

2 Answers

Accepted answer first, then by votes
117

Accepted answer

Start by separating chemical degradation from physical degradation, because they fail differently and they are detected differently. Chemical degradation changes the molecule and shows up as new peaks on a chromatogram. Physical degradation aggregates the molecule and often shows up as nothing at all on reverse-phase HPLC, because the aggregate never makes it onto the column.

For the solid state, residual moisture is the dominant variable. A cake at two per cent water is considerably more stable than the same cake at six per cent, because water is both a reactant in hydrolysis and a plasticiser that lowers the glass transition temperature. This is why a desiccant in the outer packaging is not theatre, and why opening a cold vial in a humid room is a genuine error — you condense water onto the cake.

Reported and extrapolated stability by condition

StateConditionUsable windowBasis
Lyophilised solid−20 °C, sealed, dry24–36 monthsSupplier guidance
Lyophilised solid2–8 °C, sealed12–24 monthsSupplier guidance
Lyophilised solid25 °C, sealed4–8 weeksExtrapolated (Arrhenius)
Lyophilised solid40 °C, sealed1–2 weeksExtrapolated
Solution, preserved2–8 °C28 daysUSP microbiological convention
Solution, preserved25 °C3–7 daysExtrapolated
Solution, unpreserved2–8 °C24 hoursUSP microbiological convention

Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.

Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.

General guidance on lyophilised peptide storage from the major synthesis houses converges on minus twenty degrees for long-term storage of solids and refrigerated storage for solutions in use, with the explicit note that repeated freeze-thaw of solutions should be avoided. It is consistent advice precisely because it follows from the chemistry rather than from a study.

The limitation is that you cannot detect slow aggregation by eye until it is well advanced, so a clear vial is weak evidence of an intact one.

If the material arrived warm and it was lyophilised, test it and proceed on the result. If it arrived warm and it was in solution, the result is more likely to be interesting than reassuring.

shareimprove this answerflag
RS
answered · acceptedrota_site55k385 Sept 2025
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
45

It helps to be literal here: the honest answer is that published stability data for these specific molecules in a research-grade presentation essentially does not exist, so what you get is extrapolation from the licensed formulations and from general peptide chemistry. That extrapolation is reasonable. It is still extrapolation.

The 28-day figure for a reconstituted preserved vial is microbiological, not chemical. Chemically, a well-behaved peptide at 5 mg/mL at 4 °C will typically lose well under a per cent of content per month. The reason to respect the date is bioburden, and bioburden is a function of how many times you have opened it, not of the calendar.

On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.

The Arrhenius relationship underpinning accelerated stability testing is the basis of ICH Q1A, which is why accelerated studies at 40 °C and 75 per cent relative humidity are used to predict shelf life at 25 °C. The same relationship lets you reason about a warm transit lane, with the same caveats about extrapolation.

Worth stating: research-use-only material has no stability programme behind it at all, so any beyond-use date you apply is your own construct.

Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.

shareimprove this answerflag
LC
answeredlyoph_cake95k25817 Sept 2025
2Good answer, but the confidence interval in the cited trial is wider than implied. – rota_site 9 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.